---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-092586"
form_type: "8-K"
ticker: "TLSI"
cik: "0001826667"
company_name: "TriSalus Life Sciences, Inc."
filed_at: "2023-08-16T23:59:59+00:00"
generated_at: "2026-06-11T08:44:38.911509+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# TriSalus completes de-SPAC merger; FDA asks for additional PERIO-01 dose study

## Summary
- Merger closed Aug 10, 2023; MTAC renamed TriSalus Life Sciences, trades on Nasdaq as TLSI and TLSIW.
- Gross proceeds ~$42.9M from trust ($2.7M) and PIPE ($40.15M); ~$9.4M redeemed by MTAC stockholders.
- Sponsor earnout shares subject to price milestones ($15-$30) over 5 years; lock-up 365 days or $12 trigger.
- FDA acknowledged safety of SD-101 with PEDD but requires additional dose-optimization; NDA submission beyond 2025.
- Co plans 40-50 patient study for PERIO-01; Phase 2 initiation targeted in 2023 but subject to change.

## SEC filing metadata
- accession: 0001104659-23-092586
- form_type: 8-K
- ticker: TLSI
- cik: 0001826667
- company_name: TriSalus Life Sciences, Inc.
- filed_at: 2023-08-16T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 2.01, 9.01, 3.02, 4.01, 3.03, 5.01, 5.02, 5.03, 5.05, 5.06, 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826667/000110465923092586/0001104659-23-092586-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826667/000110465923092586/tm2321991d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-092586
- JSON: https://secwatch.observer/filing/0001104659-23-092586.json
- Plain text: https://secwatch.observer/filing/0001104659-23-092586.txt

## Key facts
- Governance Changes
  TriSalus Life Sciences, Inc.: Approved and adopted a new Code of Business Conduct and Ethics (effective 2023-08-10).
  - Change: code of ethics
  - Effective: 2023-08-10
  source text: on August 10, 2023, the New TriSalus Board approved and adopted a new Code of Business Conduct and Ethics applicable to all employees, officers and directors of the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1826667/000110465923092586/0001104659-23-092586-index.htm
- Governance Changes
  TriSalus Life Sciences, Inc.: Filed Certificate of Incorporation with amendments proposed by Charter Proposal (effective 2023-08-10).
  - Change: charter amendment
  - Effective: 2023-08-10
  source text: On August 10, 2023, the Company filed the Certificate of Incorporation with the Delaware Secretary of State
  evidence_url: https://www.sec.gov/Archives/edgar/data/1826667/000110465923092586/0001104659-23-092586-index.htm
- Governance Changes
  TriSalus Life Sciences, Inc.: MTAC ceased to be a shell company as a result of the Business Combination (effective 2023-08-10).
  - Change: shell status
  - Effective: 2023-08-10
  source text: MTAC ceased to be a shell company (as defined in Rule 12b-2 of the Exchange Act) as of the Closing
  evidence_url: https://www.sec.gov/Archives/edgar/data/1826667/000110465923092586/0001104659-23-092586-index.htm
- Governance Changes
  TriSalus Life Sciences, Inc.: Adopted Amended and Restated Bylaws (effective 2023-08-10).
  - Change: bylaw amendment
  - Effective: 2023-08-10
  source text: also adopted Amended and Restated Bylaws on August 10 , 2023 (the “Bylaws”), which replaced MTAC’s Amended and Restated Certificate of Incorporation and bylaws in effect as of such time
  evidence_url: https://www.sec.gov/Archives/edgar/data/1826667/000110465923092586/0001104659-23-092586-index.htm
- M&A Transactions
  TriSalus Life Sciences, Inc. underwent a change of control (closed 2023-08-10).
  - Action: change of control
  - Closing: 2023-08-10
  source text: As a result of the consummation of the Business Combination, a change of control of MTAC has occurred, and the stockholders of MTAC as of immediately prior to the Closing held 9.7% of the outstanding shares of New TriSalus Common Stock immediately following the Closing.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1826667/000110465923092586/0001104659-23-092586-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.